Suez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Therapeutic efficacy of Ganoderma Lucidum on Thioacetamide-Induced Hepatic Fibrosis through Inhibition of TGF-β1 signaling in Male Rats.11313743810.21608/rpbs.2020.51148.1081ENHanan M.HassanPharmacology and Biochemistry, Faculty of pharmacy Delta University for science and Technology. International Costal Road, Gamasa City, Mansoura, Dakhliya, Egypt.0000-0003-0464-0809Sahar EElswefyDepartment of Pharmacology and Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, International Costal Road, Gamasa City, Mansoura, Egypt.
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, EgyptJournal Article20201126The anti-fibrosis efficacy of Ganoderma lucidum (GL) was investigated on thioacetamide (TAA)-induced liver fibrosis. Experimental fibrosis was induced by (200 mg/kg TAA, i.p.) twice weekly for 6 weeks in male Sprague-Dawley rats. GL was administered to TAA rats, either as (250/500 mg/kg, i.p) daily for further 3 weeks. Repeated administration of TAA caused liver fibrosis evidenced by significant elevation of hepatic TGF-β1 accompanied by an increase in the hydroxyproline content, oxidative stress levels and liver biomarkers. Contrarily, GL treatment significantly reduced ALT, AST, total bilirubin, MDA, NO concentrations and restored SOD activity. H & E and Masson trichrome staining confirmed that GL suppressed liver fibrosis, inflammation and attenuated the histopathological alterations. GL also elicited a statistical decrease in TGF-β1 level and hydroxyproline content with a concomitant decline in NFk-B and α-SMA immunoexpression in the TAA treated rats. Furthermore, GL downregulated TNF-α and IL-1β levels in TAA-treated rats compared to the control group. Conclusion: GL possesses a pronounced protective activity against TAA-induced fibrosis in rats; It significantly inhibits oxidative stress, inflammation and diminishes fibrosis by: inhibiting NFk-B activation, reducing TGF-β mediated by PI3K-AKT pathway thus restoring the liver function, the effect was in a dose dependent manner.https://rpbs.journals.ekb.eg/article_137438_b290383af3dccee28a81a040f127ff8b.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Cardiotoxicity of Naja nubiae snakebites: A review and consideration142013743910.21608/rpbs.2019.18479.1044ENMohammed ElsayedM.Pharmacology and toxicology, Faculty of Pharmacy, Suez canal University, Ismailia, Egypt0000-0001-7523-3405MonaEl-AzabDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt0000-0003-4982-445XYasserMostafaPharmacology and Toxicology Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.0000-0001-5394-5559TarekRahmyDepartment of Zoology, Faculty of Science, Suez Canal University, Ismailia, EgyptJournal Article20191020Snake bites are considered as one of the serious challenges facing people living in areas near the place of those snakes’ habitat. Antivenin treatment though being the gold standard against expected toxicities, is not always present especially when toxicology centers are out of reach during cases of acute envenomation and injuries. Nubian spitting cobra or Naja nubiae is known to be major threat of hematological and cardiac toxicities in Upper Egypt. Although the main characteristic of its venom is being neurotoxic, cardiotoxicity due to high content of cardiotoxins and generation of reactive oxygen species is profound in cases of toxicity by envenomation. This review highlights the structure of cardiotoxins as the main component of Naja nubiae venom and lists different possible cardiotoxicities associated with it especially myocardial infarction and myocarditis. As well as possible future recommendations for those who are in risk of inhabiting or travelling to where these snakes are found.https://rpbs.journals.ekb.eg/article_137439_028cb345bc407a30e3ca31f7408ed475.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Drug Delivery from Microsponges: A Review Article212713744110.21608/rpbs.2020.23585.1054ENShadeedGadFaculty of Pharmacy - Suez Canal University0000-0001-7714-2267GhadaElosailyDept. of Pharmaceutics
Faculty of Pharmacy,
Al-azhar University,RadwaMahrousDept. of Pharmaceutics
Faculty of Pharmacy,
MTIYasserMoustafaPharmacology and Toxicology Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.0000-0001-5394-5559ElsayedKhafagyDept. of Pharmaceutics
Faculty of Pharmacy,
Suez Canal UniversityJournal Article20200206Microsponges are micro-porous particles, used mainly for topical and recently for oral administration. Microsponges have many advantages which make it a versatile drug delivery system. Microsponges can suspended or entrap a wide variety of substances and then be incorporated into a formulated product such as a gel, cream, liquid, or powder. Moreover, they may enhance stability, reduce side effects and modify drug release related to its porous structure which allows the active ingredient to sustain over time. This article aims to provide details about microsponges including the method of preparation, characterization, mechanism of drug release from microsponges, different formulation, and process factors, and a few applications about microsponges that are either proven or under research. Besides, microsponges improve stability, increase elegance, and enhance formulation flexibility. Previous studies were done and confirmed that microsponges are non-irritant, non-allergenic, non-mutagenic, and non-toxic. This technology is being used currently in cosmetics, sunscreens, and prescription products. Therefore, the microsponges based drug delivery technology is likely to become a valuable drug delivery matrix substance for various therapeutic applications in the future.https://rpbs.journals.ekb.eg/article_137441_1145d10cd7bd92a97a0c33f2ff319c3d.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Formulation factors of starch-based nanosystems preparation and their pharmaceutical application283913744210.21608/rpbs.2020.51097.1080ENAhmedGardouhDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jadara University, Irbid 221110, Jordan.0000-0002-5387-1614Ahmed S.G.Srag El-Dinpharmaceutics department, faculty of pharmacy delta university for science and technology0000-0002-9924-3154YasserMoustafaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.0000-0001-5394-5559ShadeedGadDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.0000-0001-7714-2267Journal Article20201125Starch-based nanosystems are considered a talented nanocarrier for drug delivery owing to their small particle size, biodegradability, and biocompatibilities. Starch-based nanosystems showed enhancement in biological activity, solubility, entrapment efficiency, and in-vitro release of several drugs. Starch-based nanosystems are categorized into two types; starch nanocrystals and starch nanoparticles. The difference between starch nanocrystals and starch nanoparticles will be summarized. Numerous techniques are employed to formulate starch-based nanosystems including chemical and physical methods. This review summarizes the existing knowledge on; a number of techniques used to formulate starch-based nanosystems, factors affecting each technique, and the advantages of combining both physical and chemical methods on the formulation time and physicochemical properties of the starch-based nanosystems. Besides, most innovative information regarding starch-based nanosystems modification on increasing entrapment efficiency will be discussed. Furthermore, applying starch-based nanosystems as effective drug delivery nanocarriers for delivering drugs and bioactive elements to improve their bioavailability will be abridged in this review.https://rpbs.journals.ekb.eg/article_137442_af252dfbca27ef0b32365e6e1510bd42.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Colloidal delivery of drugs: present strategies and conditions405113762110.21608/rpbs.2020.30372.1070ENNahedSallamDepartment of Pharmaceutics, National Organization for Drug Control and Research, EgyptRaniaSanadDepartment of Pharmaceutics, National Organization for Drug Control and Research, EgyptEl-SayedKHAFAGYDepartment of Pharmaceutics, Faculty of Pharmacy, Suez Canal University, EgyptMahgoubAhmedDepartment of Molecular Drug Evaluation, National Organization for Drug Control and Research, EgyptMamdouhGhourabDepartment of Pharmaceutics, Faculty of Pharmacy, Suez Canal University, Egypt.ShadeedGadFaculty of Pharmacy - Suez Canal University0000-0001-7714-2267Journal Article20200625In this article, we offer a summary of a broad variety of colloidal drug delivery systems with a special emphasis on vesicular used in testing or theoretically useful as carrier systems for medicines or active biomolecules or as cell carriers with therapeutic use. They provide several significant details of the currently developed drug delivery systems for academic or clinical applications. This series of systems are commonly used due to outstanding drug tracking, continuous and regulated release behavior, improved drug molecules clogging performance, avoidance of product hydrolysis or enzymatic degradation, and therapeutic efficacy improvements. Such characteristics aid in the discovery of suitable carrier structures for the transmission of medicines, cells, and genes in various fields. Colloidal drug delivery systems play a significant role in drug delivery. In my opinion, all colloidal carriers present notable characteristics after application. These vesicles can deliver an active compound through the biological membranes via absorption, fusion, and to raise the quantity of permeated drugs compared with conventional formulations.https://rpbs.journals.ekb.eg/article_137621_eaa379ed4abced90377e7be92bb38138.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Self - Emulsifying Drug Delivery System: A Novel Approach for Oral Delivery of Poorly Water Soluble Drugs525814465210.21608/rpbs.2021.52929.1086ENAhmed MohammedNasefDepartment of pharmaceutics, Faculty of pharmacy, Suez Canal University, Ismailia, EgyptJournal Article20201209Self nano emulsifying drug delivery systems (SNEDDs) gained much attention in the last decades since, such systems considered one of the most favorable and efficient approaches to enhance solubility, increase drug absorption and hence, enhance its oral bioavailability of poorly water soluble (lipophilic) drug moieties. Owing to their unique properties and advantages over the other conventional dosage forms, many literatures investigate the change physicochemical properties, pharmacokinetic and pharmacodynamics of self emulsifying formulation compared to both pure drug and its conventional dosage form and always reported significant improvement using SNEDDs. This review discus the composition, advantages and mechanism of action of liquid SNEDDs and some techniques used for solidification of liquid formulations to overcome its drawbacks.https://rpbs.journals.ekb.eg/article_144652_97cb0c0d65c5fc223691044c261b0c4b.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Drug Delivery Systems for Topical treatment of Inflammatory Skin Diseases596416064810.21608/rpbs.2021.62807.1094ENShadeedGadFaculty of Pharmacy - Suez Canal University0000-0001-7714-2267MohamedDesoqiPharmacy Department, The Armed Forces Medical Complex, Qobry El Qoba, Ministry of Defense, EgyptHossamEl-SawyDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, EgyptElsayedKhafagyDept. of Pharmaceutics
Faculty of Pharmacy,
Suez Canal UniversityMamdouhGhourabDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal UniversityJournal Article20210215The skin is known to be the primary intact skin layer for the application of cosmetics and medicines. These nanocarriers, however, can enhance the distribution of molecules through hair follicles or impart a regulated pattern of release by making depots on the skin.. moreover, Many challenges may potentially face the topical delivery of medicaments through either the healthy or diseased skin. This is mainly owing to the strong protection offered by the barriers made of the skin. This paper displays the blocking nature of the skin, the difficult conditions of skin inflammatory diseases, options of effective treatment, and general categories of advanced topical drug delivery for better efficacy and safety. Solid lipid nanoparticles and other lipid-based nanocarriers are mentioned particularly with a further focus along with examples of opportunities for bioavailability enhancement of poorly absorbed active moieties and for more promising implementation in convenient and efficient topical remediation of skin inflammatory disorders.https://rpbs.journals.ekb.eg/article_160648_4d6bb0c42adfd8e4444cb9809051292a.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Anti-Diabetic Medications: A promising therapeutic approaches for the Management of NAFLD657018603610.21608/rpbs.2021.79353.1103ENAhmedIbrahimDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University,
Ismailia 41522, EgyptReem MohamedHazemDepartment of Pharmacology &Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.0000-0002-7667-9561Dina AbdelkarimAliDepartment of clinical Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia 41522, EgyptYasser MohamedMoustafaPharmacology and Toxicology Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.0000-0001-5394-5559Journal Article20210606Type 2 diabetes and Nonalcoholic fatty liver disease are two of the most common metabolic diseases in the world, with an increasing prevalence. Patients with T2DM have a two-fold increased risk of developing NAFLD, The evidence that certain antidiabetic drugs boost NAFLD/NASH in T2DM patients is growing. However, there are no specific pharmacologic treatments available. This review aims to outline the data supporting the effectiveness of anti-diabetic drugs in the treatment of NAFLD, besides providing an overview of novel anti-diabetic therapies that have been proposed to achieve this goal. Most of these anti-diabetic agents demonstrate short-term efficacy, but have shown little to no impact on hepatic histology. Only thiazolides and GLP-1 receptor agonists have shown considerable improvement in hepatic histology.https://rpbs.journals.ekb.eg/article_186036_ac11ec98d1cd53646e8fc4e87c4dca87.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101The possible protective effects and mechanisms of action of Pycnogenol: in vivo animals and human studies718018603710.21608/rpbs.2021.86406.1109ENFaten M.Al-AbkalDepartment of Pharmacology, Faculty of Pharmacy, Suez Canal UniversityDina M.KhodeerDepartment of Pharmacology &amp; Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt0000-0002-3412-4138Yasser M.A.MoustafaDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, EgyptJournal Article20210715Pycnogenol (PYC) is a plant-based extract derived from the proprietary bark of the French maritime pine (Pinus pinaster ssp. atlantica) that exerts antioxidative, anti-inflammatory, and anti-platelet effects. The standardized extract is composed of phenolic compounds (catechin, epicatechin, and taxifolin), condensed flavonoids (classed as procyanidins/ proanthocyanidins) and phenolic acids (cinnamic acids and other glycosides). these phenolic compounds after being ingested, undergo biotransformation and are broken down in the colon by microbial enzymes yielding smaller, bioavailable molecules that can then be absorbed by the colon into the bloodstream and transported to tissues and organs. The pycnogenol possess a highly protective characteristics versus various cardiovascular dysfunctions, kidney diseases, hepatic dysfunctions, neuro cognitive disorder, diabetes, reproductive dysfunction and infertility, cancer, digestive, retinal disease. The present review illustrates the effect of Pycnogenol as antioxidant and anti-inflammatory effects along with anti-tumor influence as well. Pycnogenol was concluded to act as an antioxidant agent in different situation including heart stress, cardiovascular system abnormalities, kidney disease and hepatic disorders, so it can be used in combination with other medication such as Methotrexate to abolish its side effects.https://rpbs.journals.ekb.eg/article_186037_21ef2edad594398122d9a7e8de32bae1.pdfSuez Canal University, Faculty of PharmacyRecords of Pharmaceutical and Biomedical Sciences2536-98575Pharmacology-Pharmaceutics20210101Lamivudine: An antiviral drug with high risk factor for selection of resistance in HBV patients818419279510.21608/rpbs.2021.83271.1106ENMahmoud AhmedAbdelaalpharmacology and toxicology, faculty of pharmacy, sinai university, ismailia, egyptJournal Article20210630Globally, it has been reported that nearly 257 million people suffer from chronic Hepatitis B virus (HBV). In Egypt, HBV has been classified as a moderate endemic where 4% of the population presented with chronic HBV. Long term Lamivudine (LMV) monotherapy has been found to develop resistant strains of HBV where the polymerase gene specifically is mutated (i.e., YMDD as a primary mutation). This review aimed to determine the correlation between LMV therapy and development of resistance in chronic HBV patients and to investigate the genes responsible for LMV resistance. LMV as an antiviral therapy has a fair response rate in the studied patients with 20% of the population has significant signs of mutation according to previous studies in Egypt . Unfortunately, the long duration treatment with LMV leads to development of LMV resistant mutations altering the efficacy of the drug and a rescue drug must be used immediately.<br /> <br /> Keywords: HBV, LMV, YMDD, Mutation, Resistance.https://rpbs.journals.ekb.eg/article_192795_7b53a52bd4b1571c707a42155dd4efcf.pdf